Anakinra, una alternativa potencial en el tratamiento de la infección respiratoria grave por SARS-CoV-2 refractaria a tocilizumab

Figuero-Pérez, Luis; Olivares-Hernández, Alejandro; Escala-Cornejo, Roberto A; Terán-Brage, Eduardo; López-Gutiérrez, Álvaro; Cruz-Hernández, Juan J.
Reumatol. clín. (Barc.) ; 17(10): 559-561, Dic. 2021. ilus, tab
Artículo en Español | IBECS (España) | ID: ibc-213367

Documentos relacionados

  1. Management of post-mortem examination in SARS-CoV-19 infections.
  2. Angiotensin-converting enzyme 2-at the heart of the COVID-19 pandemic.
  3. Need for Speed: From Human SARS-CoV-2 Samples to Protective and Efficacious Antibodies in Weeks.
  4. Characterization of a mouse-adapted strain of bat severe acute respiratory syndrome-related coronavirus.
  5. SARS-CoV-2: Combating Coronavirus Emergence.
  6. SARS2020: an integrated platform for identification of novel coronavirus by a consensus sequence-function model.
  7. [Structure of SARS-CoV-2 and treatment of COVID-19].
  8. Reduced neutralization and Fc effector function to Omicron subvariants in sera from SARS-CoV-1 survivors after two doses of CoronaVac plus one dose subunit vaccine.
  9. Opciones terapéuticas en el manejo de la COVID-19 grave: una perspectiva de Reumatología
  10. Heteromultimeric sarbecovirus receptor binding domain immunogens primarily generate variant-specific neutralizing antibodies.